Klaus Breiner

Co-founder and Managing Director

2021

We are an independent Swiss VC Firm. Our Pureos Bioventures funds focus on private biotech companies in Switzerland and broader Europe developing innovative drugs for severe diseases.

Non-executive Director

2021

Managing Partner

2017

BB Pureos Bioventures is a new venture capital franchise to exclusively invest in private innovative drug development companies with a special emphasis on the next generation of biological drugs and drug formats. For Pureos, we have assembled a new team of venture managers, biotech founders, scientists and big pharma & biotech executives, with long-standing experience in biologic drug development, company building and healthcare investing, and a wide-spanning network. We started Pureos as a joint venture with the Bellevue Group, which has a long tradition of healthcare investing, and is one of the largest and most experienced healthcare investors worldwide.

Partner

2004

Selected Investments: Alpex Pharma SA (secondary sale), AM-Pharma BV, Cadence Pharmaceuticals, Inc. (later publicly listed, subsequently acquired by Mallinckrodt), Neose Technologies, Inc. (asset acquisition), Orthocon Inc.(later merged to become AbyRx Inc.), Vaximm AG

Co-Founder & Vice-Chairman (Executive Chairman till mid-2016)

2008 - 2022

Board Director

2006 - 2021

Senior Adviser Private Equity

2004 - 2021

Board Director

2007 - 2020

Board Director

2011 - 2019

Board Director

2007 - 2011